Neurogene reaffirms Embolden data for 2H 2027, cash runway into Q1 2029
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
2 stories
Neurogene's third-quarter update held its Rett syndrome gene therapy timeline steady while R&D spending and net loss both increased year over year.
SEC filing (8)
The ophthalmology-focused hire, effective September 8, 2026, comes with a $350,000 base salary and a stock option grant of up to 55,000 shares.
SEC filing